Cognition Therapeutics (CGTX): Pipeline, Trials & Analysis
A detailed profile of Cognition Therapeutics (CGTX) analyzing its pipeline, financials, and lead drug zervimesine (CT1812), a sigma-2 modulator for Alzheimer's and DLB, with 2025-2026 updates including Phase 3 plans, SHIMMER publication, and START trial enrollment.